What the FDA Relabeling of Abacavir Means for You and Your Patient

HLA-B*5701 Correlations

November 2008

However, there is a significantly lower odds ratio, down to 0.03, for abacavir hypersensitivity reactions by prospective screening for HLA-B*5701 allele in immunologically-confirmed hypersensitivity reactions.

Prospective screening and exclusion of patients with the HLAB*5701allele reduces the incidence of abacavir hypersensitivity reactions.

< Previous Slide

HLA-B*5701 Correlations

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?